BioSpace News Archive

Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), has announced the appointment of Jon Zwinski as General Manager and Chief Executive Officer of Chiesi USA to advance the company’s global therapeutic efforts. Effective Jan. 1, 2021, Mr. Zwinski will succeed President and CEO K

The American Cancer Society has named four new members and elected five new officers to its board of directors, with all terms beginning on January 1, 2021.

ixlayer, a leader in technology-based solutions for diagnostic testing, announced that its technology was selected by the Chan Zuckerberg Biohub and Stanford University to power their Community Alliance to Test Coronavirus at Home (CATCH) Study, a large-scale research collaboration led by Stanford Medicine for testing and tracking the coronavirus throughout the greater San Francisco Bay Area.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it will release financial results for its fiscal 2020 fourth quarter ended September 30, 2020 after market close on Thursday, December 17, 2020.

Walgreens Boots Alliance, Inc. will release its fiscal 2021 first quarter earnings results at 7 a.m. Eastern time Thursday, Jan. 7, 2021 followed by a one-hour conference call with WBA management beginning at 8:30 a.m. Eastern time.

Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD).

Usona Institute has published a multigram-scale process describing the synthesis of 5-MeO-DMT in the open-access journal ACS Omega . The newly developed procedure emphasizes scalability, controllability, and reproducibility with detailed chemical and physical characterization to support further clinical research with 5-MeO-DMT as a potential treatment for mental health conditions such as depression, anxiety, addictio

iXensor Co., Ltd. (6734.TWO) Global fertility rates are dropping at alarming rates and the ongoing Covid-19 pandemic is making the situation even worse.

Carlsmed, Inc., today announced it has been granted 510(k) clearance and Breakthrough Device Designation by the FDA for its aprevo patient specific interbody devices for the correction of adult spinal deformity. The Carlsmed aprevo device is the first implant ever to receive both Breakthrough Device Designation and 510(k) market clearance from the FDA. To meet t

Boston Cell Standards, announced today that it will present the results of a Canadian national study that tested the first system of reference materials for standardization of estrogen receptor (ER) testing for breast cancer.